Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy iTeos Therapeutics (ITOS) stocks in Canada

Learn how to easily invest in iTeos Therapeutics stocks.

iTeos Therapeutics is a biotechnology business based in the US. iTeos Therapeutics stocks (ITOS.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $26.4 – a decrease of 6.66% over the previous week. iTeos Therapeutics employs 74 staff and has a trailing 12-month revenue of around $104.3 million.

How to buy shares in iTeos Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ITOS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy iTeos Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

iTeos Therapeutics stock price (NASDAQ:ITOS)

Use our graph to track the performance of ITOS stocks over time.

iTeos Therapeutics shares at a glance

Information last updated 2022-01-17.
Latest market close$38.15
52-week range$17.43 - $52.43
50-day moving average $37.93
200-day moving average $28.44
Wall St. target price$50.20
PE ratio 99.3985
Dividend yield N/A (0%)
Earnings per share (TTM) $0.40

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

iTeos Therapeutics price performance over time

Historical closes compared with the close of $38.15 from 2022-01-18

1 week (2022-01-12) -6.66%
1 month (2021-12-17) -11.69%
3 months (2021-10-19) 38.32%
6 months (2021-07-19) 58.63%
1 year (2021-01-19) 4.81%
2 years (2020-01-15) N/A
3 years (2019-01-15) N/A
5 years (2017-01-15) N/A

Is iTeos Therapeutics under- or over-valued?

Valuing iTeos Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of iTeos Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

iTeos Therapeutics's P/E ratio

iTeos Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 99x. In other words, iTeos Therapeutics shares trade at around 99x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

iTeos Therapeutics's EBITDA

iTeos Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $17 million.

The EBITDA is a measure of a iTeos Therapeutics's overall financial performance and is widely used to measure a its profitability.

iTeos Therapeutics financials

Revenue TTM $104.3 million
Operating margin TTM 15.7%
Gross profit TTM $0
Return on assets TTM 1.61%
Return on equity TTM 4.17%
Profit margin 14.14%
Book value $10.55
Market capitalisation $1.4 billion

TTM: trailing 12 months

iTeos Therapeutics share dividends

We're not expecting iTeos Therapeutics to pay a dividend over the next 12 months.

iTeos Therapeutics overview

Iteos Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts. .

Stocks similar to iTeos Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site